SOURCE: CFN Media

CFN Media

February 28, 2017 08:30 ET

InMeds Bioinformatics Platform Powers Cannabinoid Drug Development -- CFN Media

SEATTLE, WA--(Marketwired - Feb 28, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, today announced the publication of an article examining InMed Pharmaceuticals Inc.'s (OTCQB: IMLFF) (CSE: IN) innovative bioinformatics platform, its recent licensing deal, and how the platform fits with the rest of the company's initiatives.

InMed Pharmaceuticals' proprietary in-silico Bioinformatics Database Assessment Tool leverages extensive databases and proprietary algorithms to rapidly identify cannabinoid combinations that are likely to have an effect on specific diseases. By doing so, the platform helps drug development companies shorten the drug discovery period, reduce the costs, and increases the likelihood of success from the onset of drug development.

The platform has three core components:

1. Comprehensive algorithms to integrate data from numerous bioinformatic databases.

2. A database on the structure of currently approved pharmaceutical products.

3. An extensive database of over 90 individual cannabinoid drugs found in cannabis.

InMed's data included in its bioinformatics assessment tool are derived from both public and proprietary sources and include protein-protein interactions, gene regulation, epigenetic modification, cell signal networks, and metabolomics. Using proprietary algorithms the platform establishes gene and protein-protein interaction networks to identify multi-target based approaches for specific diseases.

In addition to leveraging the platform for its own drug pipeline, the company signed a term sheet for its first potential licensing deal with Revive Therapeutics Ltd., which is developing cannabinoid-based therapeutics for kidney diseases.

Please follow the link to read the full article: http://www.cannabisfn.com/inmeds-bioinformatics-platform-powers-cannabinoid-drug-development/

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

Contact Information